Abstract
While the battle rages on about the endogenous repair capacity in the heart, solid work is progressing to take the promising exogenous pluripotent stem cells toward a clinical application. We know that the human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) can reliably be differentiated into cardiac myocytes; protocols are being defined, refined, and scaled up continuously. However, the hard grind and expense of producing the bulk of cardiomyocytes required, delivering them in a way that enables retention and using a clinically relevant model, is demanding and, arguably, unglamorous work. Certainly, Geron appears to have held that opinion when it abandoned the effort as unprofitable in 2011. In their recent Nature paper,1 Murry and Laflamme’s group report important progress toward this goal by producing significant quantities of muscle in the hearts of macaque monkeys using hESC-derived cardiomyocytes (hESC-CMs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
